Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study

BACKGROUND: Bullous pemphigoid (BP) is a common subepidermal bullous disorder that lacks adequate treatment alternatives. Dupilumab, an anti-interleukin (IL) 4 receptor α antibody blocking Th2 molecules IL-4 and 13, has been used off-label and shown to be effective in refractory BP cases. METHODS: B...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Si-Hang, Shan, Ying, Li, Si-Zhe, Zuo, Ya-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399451/
https://www.ncbi.nlm.nih.gov/pubmed/37545503
http://dx.doi.org/10.3389/fimmu.2023.1165106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399451/
https://www.ncbi.nlm.nih.gov/pubmed/37545503
http://dx.doi.org/10.3389/fimmu.2023.1165106

Ejemplares similares